Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8296 to 8310 of 8916 results

  1. Implantable cardioverter defibrillators (ICDs) for the treatment of arrhythmias (TA11)

    This guidance has been replaced by NICE technology appraisal guidance 95 [Replaced by NICE technology appraisal guidance 314]. 

    Withdrawn guidance

  2. Rituximab for the treatment of follicular lymphoma (TA110)

    This guidance has been updated and replaced by NICE technology appraisal guidance 243.

    Withdrawn guidance

  3. Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer (TA112)

    This guideline has been updated and replaced by NICE guideline NG101.

    Withdrawn guidance

  4. Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (TA107)

    This guideline has been updated and replaced by NICE guideline NG101.

    Withdrawn guidance

  5. Paclitaxel for the adjuvant treatment of early node-positive breast cancer (TA108)

    This guideline has been updated and replaced by NICE guideline NG101.

    Withdrawn guidance

  6. Docetaxel for the adjuvant treatment of early node-positive breast cancer (TA109)

    This guideline has been updated and replaced by NICE guideline NG101.

    Withdrawn guidance

  7. Trabectedin for the treatment of relapsed ovarian cancer (TA222)

    This guidance has been updated and replaced by NICE technology appraisal guidance 389.

    Withdrawn guidance

  8. Golimumab for the treatment of methotrexate-naive rheumatoid arthritis (terminated appraisal) (TA224)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Withdrawn guidance

  9. Bivalirudin for the treatment of ST-segment-elevation myocardial infarction (TA230)

    This guideline has been updated and replaced by NICE guideline NG185.

    Withdrawn guidance

  10. Wound care - debriding agents (TA24)

    This guidance has been replaced by NICE guideline CG74.

    Withdrawn guidance

  11. Roflumilast for the management of severe chronic obstructive pulmonary disease (TA244)

    This guidance has been updated and replaced by NICE technology appraisal guidance 461.

    Withdrawn guidance

  12. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (TA241)

    This guidance has been updated and replaced by NICE technology appraisal guidance 425.

    Withdrawn guidance

  13. Pharmalgen for the treatment of bee and wasp venom allergy (TA246)

    This guidance has been withdrawn because Pharmalgen products no longer have a marketing authorisation in the UK.

    Withdrawn guidance

  14. Guidance on the use of gemcitabine for the treatment of pancreatic cancer (TA25)

    This guidance has been replaced by NICE guideline NG85.

    Withdrawn guidance

  15. Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes (TA248)

    This guidance has been updated and replaced by NICE guideline NG28.

    Withdrawn guidance